Skip to results

Expected publication date

Expected publication date

Area of interest

Area of interest

Type

Type

Guidance programme (1 selected)

Guidance programme

Showing 41 to 50 of 320

Guidance, NICE advice and quality standards in development
TitleTypeExpected publication date
Benralizumab with corticosteroids for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis ID6266Technology appraisal guidanceTBC
Bevacizumab gamma for treating wet age-related macular degeneration [ID6320]Technology appraisal guidance
Bevacizumab in combination with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer [ID1145]Technology appraisal guidance
Bimatoprost implant for treating open angle glaucoma or ocular hypertension in people who are unsuitable for topical treatments [ID6180]Technology appraisal guidanceTBC
Bimekizumab for treating moderate to severe hidradenitis suppurativa [ID6134]Technology appraisal guidance
Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia with no measurable residual disease [ID6405]Technology appraisal guidance
Botulinum toxin type A for treating upper or lower limb focal spasticity associated with stroke [ID768]Technology appraisal guidanceTBC
Brentuximab vedotin with doxorubicin, dacarbazine and vinblastine for previously untreated late-stage classical Hodgkin lymphoma (including Review of TA594) [ID6334]Technology appraisal guidanceTBC
Burosumab for treating FGF23-related hypophosphataemia in tumour-induced osteomalacia [ID3924 ]Technology appraisal guidanceTBC
Burosumab for treating X-linked hypophosphataemia in adults [ID3822]Technology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All